# **Continuous Glucose Monitoring (CGM)**

#### Goal(s):

- Restrict use of CGM to medically appropriate conditions funded under the Oregon Health Plan
- Promote use that is consistent with the Health Evidence Review Commission guideline note 108

#### **Length of Authorization:**

Up to 12 months

### **Requires PA:**

All continuous glucose monitoring supplies

## **Covered Alternatives:**

- Current PMPDP preferred drug list per OAR 410-121-0030 at www.orpdl.org
- Searchable site for Oregon FFS Drug Class listed at www.orpdl.org/drugs/

Table 1. Quantity limits for continuous glucose monitoring

Product	Receiver/Reader*	Transmitter	Sensors	
Cost-effective CGM				
Dexcom 6 or 7	1 receiver every 5 years	G6: 1 transmitter every 90 days G7: NA	1 sensor every 10 days	
Freestyle Libre	1 reader every 5 years	NA	1 sensor every 14 days	

<sup>\*</sup>Receivers and readers may not be needed if the member is able to use a compatible smartphone

Ap	Approval Criteria				
1.	What diagnosis is being treated?	Record ICD10 code.			
2.	Is the request for diabetic supplies in excess of amounts outlined in Table 1?	Yes: Pass to RPh. Deny; DME in excess of quantity limit.	<b>No:</b> Go to #3		
3.	Is the request for continuation of therapy previously approved by FFS?	Yes: Go to Renewal Criteria	<b>No:</b> Go to #4		
4.	Has the patient received (or will receive) diabetes education specific to the use of CGM?	Yes: Go to #5  Document provider attestation	No: Pass to RPh. Deny; medical appropriateness		
5.	Is the request for type 1 diabetes mellitus?	<b>Yes</b> : Go to #6	<b>No:</b> Go to #7		

Approval Criteria				
<ul> <li>6. Is there documentation for any of the following: <ul> <li>a. age of 21 years or less</li> <li>b. current pregnancy or plans to become pregnant within 6 months</li> <li>c. current use of an insulin pump</li> <li>d. HbA1c ≥ 8.0% (in the past 3 months or prior to CGM use) OR</li> <li>e. Frequent, severe, or impaired awareness of hypoglycemia</li> </ul> </li> </ul>	<b>Yes:</b> Go to #9	No: Pass to RPh. Deny; medical appropriateness		
7. Is the request for gestational or type 2 diabetes AND is the patient using short or intermediate acting insulin?	Yes: Go to #8	No: Pass to RPh. Deny; medical appropriateness		
<ul> <li>8. Is there documentation for any of the following:</li> <li>a. HbA1c ≥ 8% (in the past 3 months or prior to CGM use)</li> <li>b. Frequent, severe, or impaired awareness of hypoglycemia OR</li> <li>c. Diabetes-related complications (e.g., peripheral neuropathy, cardiovascular disease, end-organ damage, etc)</li> </ul>	<b>Yes:</b> Go to #9	No: Pass to RPh. Deny; medical appropriateness		
9. Is the request for a cost-effective product OR will the prescriber switch to a cost-effective product (Table 1)?	Yes: Approve necessary supplies for the preferred product for 6 months or for the duration of the pregnancy (up to 12 months)	No: Pass to RPh. Deny; cost-effectiveness for DME.		

Renewal Criteria				
Is the request for continuation of CGM after a pregnancy?	<b>Yes:</b> Go to #2	<b>No:</b> Go to #3		
Does the patient meet any other criteria for approval?  Note: continuation after a pregnancy is only considered medically appropriate for members who meet other criteria for approval (see above).	Yes: Go to #3	No: Pass to RPh. Deny; medical appropriateness		

Renewal Criteria					
3. Has the member used the device for at least 50% of the time at their first follow-up visit?	Yes: Approve for 12 months  Document use based on	No: Pass to RPh. Deny; medical appropriateness			
	CGM metrics				

Implementation: 1/1/24